Tuesday, May 26, 2015

Faruqi & Faruqi Investigation: Iso Ray, Inc.

Faruqi & Faruqi, LLP the Investigation of IsoRay, Inc. and its Officers for Potential Securities Stock Fraud in Connection with the Doctoring of Study Results - ISR


Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at IsoRay, Inc. (“IsoRay” or the “Company”) (NYSE MKT: ISR).
On May 22, 2015, the market news website TheStreet.com published an article titled "IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price," which reported that "To make up for the inability to deliver revenue growth -- and prop up its stock price -- IsoRay issues a lot of promotional press releases, some of which take liberties with clinical data using clever, selective editing."  The article goes on to give the following example: IsoRay recently trumpeted a 100% survival at five years in high risk patients being treated with Cesium-131 without mentioning that the comparable five year survival rate for patients undergoing surgery alone is 98%.   
Take Action
If you invested in IsoRay stock or options  and would like to discuss your legal rights, please contact us by filling out the form below, by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330, or by sending an e-mail to rgonnello@faruqilaw.comFaruqi & Faruqi, LLP also encourages anyone with information regarding IsoRay’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

No comments:

Post a Comment